Literature DB >> 22850222

Prediction of treatment outcomes in patients with chest wall sarcoma: evaluation with PET/CT.

Yuji Nishiyama1, Ukihide Tateishi, Akira Kawai, Hirokazu Chuman, Fumihiko Nakatani, Mototaka Miyake, Takashi Terauchi, Tomio Inoue, Edmund E Kim.   

Abstract

OBJECTIVE: The aim of this study was to investigate the prognostic implications of (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography in patients with chest wall sarcoma.
METHODS: Positron emission tomography/computed tomography scans of 42 patients (mean age: 46 years) with chest wall sarcomas were analyzed. Pathologic confirmation was obtained by surgical specimens in all patients. Tumor grade assessed by Ki-67 (MIB-1) immunohistochemical analysis and expression of glucose transporter protein 1 were compared with a maximum standardized uptake value. Univariate and multivariate analyses were conducted for estimates of overall and event-free survivals.
RESULTS: The median maximum standardized uptake value of the tumor was 10.2 and the median MIB-1 index of the tumor was 32.5%. Glucose transporter protein 1 expression was found in 29 patients (69%). Univariate analyses revealed that surgery, chemotherapy, MIB-1 labeling index (cut-off 32.5%), MIB-1 grade, glucose transporter protein 1 expression and maximum standardized uptake value were possible predictors for overall and event-free survival. Multivariate analysis revealed that surgery (hazard ratio, 4.852; P = 0.017), maximum standardized uptake value (hazard ratio, 3.077; P = 0.037) and MIB-1 labeling index (hazard ratio, 6.549; P = 0.003) were independent predictors of event-free survival. In addition, surgery (hazard ratio, 4.092; P = 0.021) and maximum standardized uptake value (hazard ratio, 2.968; P = 0.027) were independent predictors of overall survival.
CONCLUSIONS: (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography allows the prediction of prognosis after treatment in patients with chest wall sarcoma and may be useful in selecting high-risk patients for more risk-adapted treatments.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22850222     DOI: 10.1093/jjco/hys116

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  3 in total

1.  Correlation between the Uptake of 18F-Fluorodeoxyglucose (18F-FDG) and the Expression of Proliferation-Associated Antigen Ki-67 in Cancer Patients: A Meta-Analysis.

Authors:  Sheng-Ming Deng; Wei Zhang; Bin Zhang; Yin-Yin Chen; Ji-Hui Li; Yi-Wei Wu
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

2.  Prognostic value of 18F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis.

Authors:  Linyan Chen; Xin Wu; Xuelei Ma; Linghong Guo; Chenjing Zhu; Qingfang Li
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

3.  Volume of interest delineation techniques for 18F-FDG PET-CT scans during neoadjuvant extremity soft tissue sarcoma treatment in adults: a feasibility study.

Authors:  Marc G Stevenson; Lukas B Been; Harald J Hoekstra; Albert J H Suurmeijer; Ronald Boellaard; Adrienne H Brouwers
Journal:  EJNMMI Res       Date:  2018-06-07       Impact factor: 3.138

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.